The importance of ether-phospholipids: A view from the perspective of mouse models  by da Silva, Tiago Ferreira et al.
Biochimica et Biophysica Acta 1822 (2012) 1501–1508
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReview
The importance of ether-phospholipids: A view from the perspective
of mouse models☆
Tiago Ferreira da Silva a,b, Vera F. Sousa a,b, Ana R. Malheiro a, Pedro Brites a,⁎
a Nerve Regeneration Group, Instituto de Biologia Molecular e Celular, Porto, Portugal
b Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal☆ This article is part of a Special Issue entitled: Metabo
Peroxisomes in Health and Disease.
⁎ Corresponding author at: Instituto de Biologia Mole
ation Group, Rua do Campo Alegre 823, 4150‐180
226074916; fax: +351 226099157.
E-mail address: pedro.brites@ibmc.up.pt (P. Brites).
0925-4439/$ – see front matter © 2012 Elsevier B.V. All
doi:10.1016/j.bbadis.2012.05.014a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 November 2011
Received in revised form 6 January 2012
Accepted 23 May 2012







Disease mechanismEther-phospholipids represent an important group of phospholipids characterized by an alkyl or an alkenyl
bond at the sn-1 position of the glycerol backbone. Plasmalogens are the most abundant form of alkenyl-
glycerophospholipids, and their synthesis requires functional peroxisomes. Defects in the biosynthesis of
plasmalogens are the biochemical hallmark of the human peroxisomal disorder Rhizomelic Chondrodysplasia
Punctata (RCDP), which is characterized by defects in eye, bone and nervous tissue. The generation and char-
acterization of mouse models with defects in plasmalogen levels have signiﬁcantly advanced our understand-
ing of the role and importance of plasmalogens as well as pathogenetic mechanisms underlying RCDP. A
review of the current mouse models and the description of the combined knowledge gathered from the his-
topathological and biochemical studies is presented and discussed. Further characterization of the role and
functions of plasmalogens will contribute to the elucidation of disease pathogenesis in peroxisomal and
non-peroxisomal disorders. This article is part of a Special Issue entitled: Metabolic Functions and Biogenesis
of Peroxisomes in Health and Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The discovery of the relationship between lack of peroxisomes and
the Zellweger syndrome [1,2] was the initial driving force to unravel
the intricacies behind peroxisome biogenesis, protein import into
peroxisomes and peroxisomal functions [3–5]. The knowledge gained
in the last three decades allowed a better understanding of the
Zellweger syndrome, the identiﬁcation of new peroxisomal disorders
and methods to perform pre- and post-natal diagnosis. Peroxisomes
are mostly known for their ability to perform (1) β-oxidation of very-
long-chain fatty acids, (2)α-oxidation of phytanic acid, (3) degradation
of hydrogen peroxide, and (4) the biosynthesis of ether-phospholipids
[6,7]. Nevertheless, the determination of the peroxisomal proteome is
still unraveling new peroxisomal proteins [8], which increases the func-
tions performed by these organelles and potentially the number of
human peroxisomal disorders.
The complexity of human peroxisomal disorders is emphasized by
(1) the lack of a unique or speciﬁc clinical presentation, (2) the variablelic Functions and Biogenesis of
cular e Celular, Nerve Regener-
Porto, Portugal. Tel.: +351
rights reserved.degrees of biochemical defects, (3) the multitude of genes that can
affect peroxisome biogenesis, (4) the absence of genotype–phenotype
correlations, and by (5) the variety of organs and tissues affected.
These features combined with a general unavailability of postmortem
material have in some cases, hindered a detailed characterization of
the tissue pathology and the mechanisms behind disease progression.
To circumvent some of these problems mouse models for human per-
oxisomal disorders have been generated. Mouse models have been
generated for most peroxisomal disorders including the Zellweger
spectrum (i.e., the Pex5, Pex2, Pex11 and Pex13 knockout mice;
[9–13]), X-linked adrenoleukodystrophy (the ATP-binding cassette,
sub-family D, member 1 (Abcd1) knockout mouse; [14–17]), Refsum
disease (the phytanoyl-CoA 2‐hydroxylase (PHYH) knockout mouse;
[18]), and D-bifunctional protein deﬁciency (the DBP or MFP2 knock-
out mouse; [19,20]). For further reading and a comprehensive listing
of the current mouse models with either peroxisome biogenesis de-
fects or β-oxidation defects see the chapter in this issue by Baes and
Van Veldhoven [21].
In this review we present the combined knowledge obtained from
the generation and characterization of mouse models for Rhizomelic
Chondrodysplasia Punctata (RCDP). RCDP is a complex disorder in
terms of clinical presentation, pathology and genetics. The disorder
is caused by an impairment in the biosynthesis of ether-phospholipids
of which plasmalogens play crucial roles that are further delineated in
this review.
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In mammalian cells ether-phospholipids represent an important
group of phospholipids. In distinction to diacyl-glycerolphospholipids,
which contain two acyl chains linked to the glycerol backbone by
ester bonds, in ether-phospholipids the acyl chain in position 1 is linked
to the glycerol backbone by either an alkyl- or an alkenyl-bond [22].
Plasmalogens are the most abundant form of ether-phospholipids and
are alkenyl-glycerophospholipids containing either an ethanolamine
or a choline moiety in the polar headgroup of the glycerol backbone
[23]. Alkyl-glycerophospholipids are less abundant, although platelet-
activating factor is abundant in neutrophils [24]. The biosynthesis of
plasmalogens is initiated in peroxisomes through the activity of two en-
zymes namely, glyceronephosphate O-acyltransferase (GNPAT) and
alkylglycerone phosphate synthase (AGPS), and is ﬁnalized in the endo-
plasmic reticulum (reviewed in [25]).
The structure and composition of plasmalogens, and in particular
the vinyl-ether bond at the sn-1 position, are thought to dictate
their role in cellular membranes. Plasmalogens have been found to
serve as (a) endogenous antioxidants, since the vinyl-ether bond is
prone to attack by oxidants, (b) mediators of membrane structure
and dynamics, since they exhibit a tendency to form nonbilayer
lipid phases, reduce surface tension and viscosity and, (c) storages
of polyunsaturated fatty acid and lipid mediators, since the sn-2 posi-
tion usually contains docosahexaenoic acid and arachidonic acid,
whose metabolism produces leukotrienes and prostaglandins. Recent
reviews on the functions and roles of plasmalogens are recommended
for further reading [26,27]. Although most experimental settings have
been performed in vitro, some studies were performed in cells de-
rived from plasmalogen-deﬁcient patients. Based on the growing
number of cells and tissues with defects caused by a plasmalogen de-
ﬁciency, and the availability of mouse models with defects in
plasmalogens the aim should now be to investigate the attributed
roles and functions of plasmalogens in target cells and tissues from
plasmalogen deﬁcient mice.
3. Plasmalogen deﬁciency in humans
The clinical presentation of RCDP typiﬁes the consequences of a
plasmalogen deﬁciency. The clinical features of RCDP patients include,
shortening of femur and humerus, cataracts, contractures, hypotonia,
atypical facial appearance (e.g., prominent forehead, anteverted nares,
long philtrum) and mental and growth retardation [28–30]. On X-ray
imaging the ectopic stippled calciﬁcations, ﬂared epiphyses and coronal
clefts in vertebral bodies further denote the defects in endochondral os-
siﬁcation present in RCDP patients [28,31,32]. Magnetic resonance im-
aging (MRI) may reveal delayed myelination, ventricular enlargement,
cerebellar atrophy, and rarely neuronal migration defects, which may
contribute to the poor neurologic prognosis of RCDP patients
[30,33–37].
In RCDP patients the impairment in plasmalogen biosynthesis can
be caused by three different defects. These defects also denote the
three forms of RCDP depending on which gene is mutated. In RCDP
type 1, mutations in PEX7 [38,39], encoding the cytosolic receptor
for peroxisomal proteins carrying the peroxisomal targeting signal 2
(PTS2), impair the import of three proteins (reviewed in [40,41]), of
which AGPS, is the cause of the impaired plasmalogen biosynthesis.
In RCDP type 2, mutations in GNPAT, encoding the ﬁrst enzyme in
the plasmalogen biosynthesis pathway, are responsible for the inabil-
ity to synthesize plasmalogens [42]. In RCDP type 3, mutations in
AGPS, encoding the second enzyme in the plasmalogen biosynthesis,
are the cause of the plasmalogen defect [43–45]. Despite this genetic
heterogeneity, all forms of RCDP share the same clinical presentation,
which indicates that the presentation of RCDP type 1patients is pri-
marily caused by the plasmalogen defects, although the defects in
β- and α-oxidation may worsen or modulate the disease state[46,47]. Although there is no obvious genotype–phenotype correla-
tion in any of the RCDP types, atypical presentations (usually lacking
the bone defects and the shortening of proximal bones) have been
described and linked to high residual levels of plasmalogens
[33,38,48–50].
In Zellweger patients the lack of functional peroxisomes also leads
to a defect in the biosynthesis of plasmalogens [51]. The clinical pre-
sentation of Zellweger patients shares some features with that of
RCDP patients, but the disease severity is greater (including hypoto-
nia, cranial and facial dysmorphism, hepato- and splenomegaly)
since all peroxisomal functions are impaired in Zellweger patients
[52–54]. MRI ﬁnding may include dysmyelination, and a severe defect
in neuronal migration seen as cerebral cortical microgyria and
pachygyria, cerebral and cerebellar neuronal heterotopias and dys-
plasias of the inferior olive [55–58]. Given the multitude of biochem-
ical abnormalities it becomes difﬁcult to attribute a given symptom or
tissue pathology to one of the biochemical defects.
Recently, reduced levels of plasmalogens have been found in X-
linked adrenoleukodystrophy (ALD) and D-bifunctional protein
(DBP) deﬁciency, two peroxisomal disorders etiologically unrelated
to RCDP [59,60]. ALD is primarily characterized by adrenal insufﬁcien-
cy, testicular atrophy and inﬂammatory demyelination of the central
nervous system [61–65]. At the biochemical level ALD is character-
ized by the accumulation of very-long-chain fatty acids due to im-
paired β-oxidation [66–68]. The molecular basis of ALD lies in
mutations in the ABCD1 gene, encoding a peroxisomal transmem-
brane protein belonging to the ATP-binding-cassette (ABC) transport-
er family, which is thought to function as a transporter of fatty acids
[69–71]. ALD has a complex presentation and variable onset of dis-
ease (see chapters in this issue by S. Kemp and A. Pujol). Recently,
a detailed study in affected areas of the brain from ALD patients has
revealed low levels of plasmalogens [59]. The deﬁciency in plasmalogens
in active demyelinating areas may act synergistically with the accumu-
lation of VLCFA and thereby exacerbate the pathology and accelerate
disease progression.
The clinical presentation of D-bifunctional protein (DBP) deﬁcien-
cy is characterized by neonatal hypotonia, seizures, craniofacial dys-
morphism and visual and hearing impairment [72,73]. At the
biochemical level the disorder is characterized by a defect in peroxi-
somal β-oxidation with accumulation of VLCFA, branched-chain
fatty acids (e.g. pristanic acid) and bile acid intermediates (di- and
trihydroxycholestanoic acids) [72,73]. Phospholipid analyses in the
brain of a DBP patient revealed a decreased amount of plasmalogens
in gray matter [60]. These ﬁndings warrant further analyses in other
DBP patients, and the investigation if the observed defects are related
to an impairment in the biosynthesis of plasmalogens or an increased
degradation. Previous work has shown that acyl-CoA generated in
peroxisomes through β-oxidation can be used in the biosynthesis of
plasmalogens [74]. This link between two distinct peroxisomal path-
ways, may suggest that impairments in peroxisomal β-oxidation can
affect plasmalogen levels as seen in ALD and DBP patients. Neverthe-
less, studies in mice with defects in peroxisomal β-oxidation did not
show a correlation between impaired peroxisomal β-oxidation and
abnormalities in plasmalogen levels [21,75]. Similarly to what has
been observed in ALD, a plasmalogen deﬁciency may increase the
nervous tissue pathology in DBP patients, although in DBP the
plasmalogen deﬁciency seems to be more pronounced in gray matter,
whereas in ALD the deﬁciency in plasmalogens is localized to affected
white matter regions.
Interestingly, reduced plasmalogen levels have also been found in
non-peroxisomal disorders. These include Alzheimer's disease [76–80],
Parkinson's disease [81], Gaucher disease [82] and Pelizaeus–Merzbacher
disease (PMD) [83]. In PMD, a leukodystrophy caused by muta-
tions in the PLP1 gene encoding the myelin proteolipid protein-1,
levels of plasmalogens are reduced in ﬁbroblasts and lymphocytes
from PMD patients [83]. In Alzheimer's disease, reduced levels of
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as in serum [85]. The investigation of plasmalogen levels in
Alzheimer's disease has revealed that the deﬁciency is pronounced
in affected brain areas, and that a secondary peroxisomal dysfunc-
tion may worsen the pathology. In addition, it has been shown that
production and accumulation of amyloid β lead to reduced activity
of AGPS with consequences in the levels of plasmalogens [77]. The
continued study of the role of plasmalogens in these disorders, will
not only contribute to a better understanding of the disease
state but also to highlight the role of plasmalogens in neu-
rodegeneration. In these disorders, and similar to what has been
proposed for ALD [86], the deﬁciency in plasmalogens is unrelated
to the primary defect which suggests that plasmalogen levels may
serve as markers for a peroxisomal dysfunction and/or for in-
creased oxidative stress.
The continued study of the pathogenesis and the mechanisms be-
hind the disease state in RCDP patients will still be of crucial impor-
tance to the understanding of the consequences of plasmalogen
deﬁciency in other neurodegenerative diseases, since the defect in
plasmalogens in RCDP is primary. The need to better understand
and characterize the RCDP pathogenesis and the mechanisms behind
the disease were one of the driving forces behind the endeavor that
several groups have undertaken to generate mouse models for
RCDP. Below we will present the current models of RCDP followed
by a description and comparison of the pathology in the tissues
most affected by a plasmalogen deﬁciency.
4. Mutants with defects in the biosynthesis of plasmalogens
4.1. The Pex7 knockout mouse
The Pex7 knockout (KO) mouse has been generated by the dele-
tion of exon 3 and ﬂanking portions of introns 2 and 3 through ho-
mologous gene recombination [87]. Pex7 KO mice on a Swiss
Webster background are born alive but display several features rem-
iniscent of RCDP patients that include dwarﬁsm and hypotonia.
Around 50% of Pex7 KO mice die within the ﬁrst 24 h. Although the
cause of death hasn't been determined, the hypotonia combined
with decreased mobility hampers feeding which will have negative
consequences during this early neonatal period. The Pex7 KO pups
that surpass the difﬁculties of this period, survive to adulthood. Tis-
sues and cells derived from Pex7 KO mice clearly showed the role of
Pex7 in PTS2-mediated import with the presence in protein extracts
of the precursor form of thiolase (encoded by the ACAA1 gene) and
AGPS. At the biochemical level the studies in Pex7 KOmice showed ex-
tremely reduced levels of plasmalogens (ranging from undetectable to
approximately 1.6% of normal levels) in erythrocytes, eyes, kidney,
heart, brain, and sciatic nerve. Studies of de novo plasmalogen bio-
synthesis in cultured mouse embryonic ﬁbroblasts (MEFs) from Pex7
KO mice showed a virtual inability to form plasmalogens which is cor-
related with an extremely reduced amount of AGPS. Additionally, at
birth the Pex7 KO mice were found to have elevated levels of VLCFA
in plasma, liver and brain. Using MEFs a defect was observed in the
β-oxidation of VLCFA and pristanic acid. Surprisingly, livers and brains
from adult Pex7 KO mice showed normal levels of VLCFA whereas ac-
cumulation of these fatty acids is still observed in spleen and kidney.
This tissue and age variability in the accumulation of VLCFA has been
postulated to be due to the existence of another peroxisomal enzyme
with thiolytic activity that can take over the defect of peroxisomal
thiolase [87]. A third biochemical defect is caused by the defect in im-
port of Phyh which impairs α-oxidation of phytanic. Nevertheless,
under normal feeding conditions the Pex7 KO defect in α-oxidation
of phytanic acid is silent, since normal rodent food only contains resid-
ual amounts of phytanic acid and phytol (the phytanic acid precursor)
which are not sufﬁcient to cause an accumulation in tissues. Only after
Pex7 KO mice are fed a diet containing phytol is the accumulation ofphytanic acid readily observed in plasma, brain and liver [87]. Similar
ﬁndings have been observed in the mouse model for Refsum's disease,
i.e., the Phyh KO [18]. The levels of phytanic acid in liver, kidney and
cerebellum of Phyh KO mice fed a control standard diet are low and
feeding a phytol-enriched diet causes amassive accumulation of phytanic
acid. Dietary restriction of phytanic acid intake in a large cohort of Refsum
patients has shown the effectiveness of the Westminster diet with 30%
of patients presenting normal levels of phytanic acid and 50% showing a
marked decreased [88].
As presented in the following section, the Pex7 KO serves as a
goodmouse model for RCDP type 1 and to study the pathology caused
by a plasmalogen deﬁciency. In addition the ability to generate a
mouse model with multiple defects (e.g. plasmalogen deﬁciency com-
bined with accumulation of phytanic acid) may be of added value
when trying to understand the pathology and mechanisms behind
the generalized loss of peroxisomal functions as seen in Zellweger pa-
tients or the Zellweger model (the Pex5 KOmouse). A similar strategy
has been used to combine a generalized accumulation of VLCFA with
a plasmalogen deﬁciency [89]. By crossing the mutant Pex7 allele
with a mutant ALD allele (Abcd1 KO), the generation of the double
mutant (Pex7:Abcd1 double KO) has shown that a plasmalogen deﬁ-
ciency modulates the pathology caused by VLCFA accumulation, and
mimics some aspects of ALD, which are not present in the ALD
mouse model. In contrast to the Abcd1 KO, the Pex7:Abcd1 double
KO showed astrocytosis, microgliosis and demyelination [89].
4.2. The Pex7 hypomorphic mouse
The generation of a hypomorphic Pex7 allele was achieved by the
introduction of a neomycin resistance cassette in the intron 2 of the
murine Pex7 locus [90]. One of the driving forces behind generating
a hypomorphic mouse was to circumvent the early lethality as seen
in Pex7 KO and Gnpat KO mice, which hampers studies with large
amounts of mice and requires large quantities of breeding pairs in
order to obtain mice for different experimental setups. Mice hetero-
zygous for the hypomorphic allele showed Pex7 transcripts that
were between 10 and 50% of wild type levels. Mice homozygous for
the hypomorphic allele on a C57BL/6:129/SvEv mixed background
did not show increased lethality and had a normal life span, although
similarly to Pex7 KO mice had reductions in body weight. Possibly in
concordance with the hypomorphic state, the biochemical defects
varied between different tissues. Plasmalogen levels were reduced
between 19 and 72% in the tissues analyzed (brain, heart and liver)
which were in accordance with a reduction in AGPS levels and re-
duced biosynthesis. Similarly to what was observed in Pex7 KO
mice, homozygous hypomorphic Pex7 mice accumulated phytanic
acid in plasma and tissues upon feeding a diet rich in phytol.
The Pex7 hypomorphic mouse mimics some aspects of the milder
forms of RCDP. These milder forms of RCDP are characterized by high
residual levels of plasmalogens which denote the relationship be-
tween plasmalogen levels and disease state [91,92]. By comparison,
the hypomorphic Pex7 mouse allows us to determine the levels of
plasmalogens necessary to develop tissue pathology and understand
which are the tissues and organs mostly dependent on plasmalogens
for normal physiology and development.
4.3. The Gnpat knockout mouse
The Gnpat KO mouse has been generated by the deletion of exons
5 to 7 through homologous gene recombination [93]. Gnpat KO mice
on a C57BL/6 background showed increased lethality during the ﬁrst
weeks after birth, with reduced body weight and impaired growth.
The activity of Gnpat in tissues and ﬁbroblasts from Gnpat KO mice
was not detectable, which led to the extremely reduced levels of
plasmalogen in brains from KO mice. The consequences of this com-
plete loss of plasmalogens included reduced levels of ﬂotillin-1 and
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connexin 43 in ﬁbroblasts. Combined with the observation that
plasmalogens are enriched in lipid rafts of a human epidermal carci-
noma cell line [94], the results of reduced expression of lipid rafts
markers suggest that in the absence of plasmalogens and despite a
normal fractionation pattern, the composition of these domains is al-
tered. The consequences of a plasmalogen deﬁciency for membrane
structure and organization are also highlighted by the abnormal ex-
pression of connexins and claudins in Gnpat KO mice [95,96]. Altered
expression of connexins 43 and 32 may affect the assembly of gap
junctions whereas the altered expression of claudins 3 and 11 may af-
fect the assembly of tight junctions. Combined these defects corrobo-
rate the role of plasmalogens in modulating membrane structure, and
organization, which can have severe consequences in target tissues
(see below).
Gnpat KO mice serve as a good mouse model for RCDP and to
study the pathology caused by a single plasmalogen deﬁciency. The
complete lack of plasmalogens results in a very severe phenotype,
similar to that of Pex7 KO mice and RCDP patients which sometimes
hinders some studies. Nevertheless, the studies performed in mice
with a virtual lack of plasmalogens may be easier to understand the
straightforward relationship between the biochemistry and the pa-
thology. The comparison of pathology and phenotype observed in
Pex7 and Gnpat KO mice lacks major differences between the two
mice. Although the genetic background is different between both
mice, they develop the same type and the same degree of pathology
(see below), indicating that in Pex7 KO mice the observed defect is
possibly solely due to the impaired biosynthesis of plasmalogens.
4.4. The blind sterile 2 mouse
The blind sterile 2 (bs2) mouse is a spontaneously arising mutation
in intron 14 of the Agps locus [97]. The mutation is hypomorphic
since it reduces expression of Agps by 85% of WT levels. At the bio-
chemical level the consequences of Agps reduced expression are
clearly seen as a decreased amount of plasmalogens in brains of bs2
mice.
The bs2mice represent a model for RCDP type 3, in which the par-
tial deﬁciency in the plasmalogen biosynthesis allows, similarly to the
Pex7 hypomorphic mouse, the study of the consequences of partial
loss of plasmalogens as seen in the mild or atypical RCDP patients.
5. Tissue pathology caused by plasmalogen loss
5.1. Eye
In the normal eye, the lens, the epithelial lens cells and the retina
are enriched in plasmalogens [98–101]. In RCDP patients congenital
cataracts are a key presentation that highlights the importance of
plasmalogens for the normal development of the lens. In addition,
atypical or mild RCDP patients may not present bone defects, but de-
velop lens opacities that lead to cataract formation [102–105]. The
importance of plasmalogens for the normal homeostasis of the eye
is also strikingly evident in the analyses of plasmalogen deﬁcient
mice. All mouse models with defects in the biosynthesis of
plasmalogens develop cataracts, regardless of having full or partial re-
ductions in plasmalogens levels.
The pathology in the eye includes (a) disruption of the polarity,
number and architecture of lens epithelial cells, (b) disorganization
of the anterior and posterior sutures with formation of lenticonus,
(c) disorganization and swelling of lens ﬁber cells, which also present
abnormalities in differentiation and maturation, and (d) a nuclear
cataract. Surprisingly, no defects have been reported in the retina, al-
though optic nerve hypoplasia has been described in Gnpat KO mice
(see below).The abnormal differentiation of lens ﬁber cells, combined with the
accumulation of cytosolic content and increased vacuolization affects
the formation of a translucent structure. In addition, abnormal cell–
cell contacts/adhesion may worsen the pathology since in addition
to the nuclear cataract, cortical lens ﬁbers also show vacuolization,
loss of cell adhesion and the formation of morgagnian globules.
Combining the histological assessment of lens from plasmalogen-
deﬁcient mice with the defects observed in connexin and claudin ex-
pression in Gnpat KO mice, it has been hypothesized that the devel-
opment of cataracts is at least in part due to abnormalities in gap
junctions that may affect the process of cell–cell contact and commu-
nication hindering the correct maturation and lens translucency.
5.2. Testis
Testis and spermatozoa are extremely enriched in ether-
phospholipids. In seminiferous tubules peroxisomes can be detected
in Leydig cells, Sertoli cells and spermatogonia but mature spermato-
zoa lack peroxisomes [106–108]. The testis is also very sensitive to
plasmalogen loss as judged by the observation that, with the excep-
tion of Pex7 hypomorphic mice all other mouse models are infertile.
The ability of Pex7 hypomorphic to reproduce may be related to a
higher level of Pex7 expression that can yield higher rates of
plasmalogen biosynthesis.
Histological changes can be seen as early as P21 and are character-
ized by a degeneration of the seminiferous tubules, and the presence
of multinucleated cells within the tubules [89,95]. The pathology is
progressive and by 2 months of age, the seminiferous tubules of
Pex7 or Gnpat KO mice are devoid of spermatogonia. The Sertoli-
only phenotype in adult KO mice indicates the importance of
plasmalogens for the normal spermiogenesis and survival of germinal
cells. A detailed study using Gnpat KO mice has revealed that a com-
plete loss of plasmalogens leads to an arrest in spermiogenesis at the
round spermatid stage [95]. The continuous degeneration of sper-
matocytes also affects Sertoli cells that show increased vacuolization.
The blood–testis barrier (BTB) is also affected in Gnpat KO mice as
judged by the leakage of intratesticular injections of a biotin tracer.
In addition dysregulation in the spatio-temporal expression of
claudin 9 and 11 not only modulates the BTB but also indicates that
a plasmalogen deﬁciency affects the correct formation and function
of tight junctions. It would be interesting to evaluate in testis, the ab-
normalities found in the expression of connexin 43 in Gnpat KO-
derived ﬁbroblasts, since alterations in gap junctions also severely af-
fect BTB and spermatogenesis and may place plasmalogens as crucial
membrane components for cell–cell contact and communication.
5.3. Bone
Skeletal abnormalities are a hallmark in the clinical presentation
of classical Zellweger and RCDP patients. The defects in proximal
limbs, vertebral bodies and generalized growth suggest that impaired
plasmalogen biosynthesis affects the process of endochondral ossiﬁ-
cation. Despite the fact that both Pex7 and Gnpat KO mice lack
plasmalogens, at birth KO mice do not show such drastic alterations
as seen in patients. Nevertheless, whole mount skeletal stainings
have revealed impairments in endochondral ossiﬁcation in newborn
pups and during embryonic development (Brites et al., unpublished
results). At birth the Pex7 hypomorphic mouse also shows defects
in ossiﬁcation and X-ray images of 3 months old mice also revealed
impaired growth.
Based on the few histological evaluations of bone in RCDP patients
and the results obtained in mice, the lack of plasmalogens seems to
affect the process of endochondral ossiﬁcation through a delay or ar-
rest in chondrocyte maturation at the pre-hypertrophic state. In addi-
tion Pex7 KO osteoclasts showed an increased number of vacuoles in
the rufﬂed border (active zone of bone remodeling) which suggests
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Nevertheless, it is still quite puzzling that in humans and during
the early neonatal period the deﬁciency is mostly seen in proximal
bone elements whereas distal bones, although ossiﬁed through the
same endochondral process are not severely affected.5.4. Nervous tissue
In humans, the impact of a plasmalogen deﬁciency on nervous tissue
and neurologic functions is highlighted not only by the alterations seen
on MRI (e.g. delayed myelination, ventricular enlargements, and cere-
bellar atrophy), and on histological changes in a few autopsy reports
(e.g. impaired neuronal migration, impaired myelination, astrocytosis)
but also by the severe spasticity and mental defects observed through-
out life in RCDP patients [109,110]. Nervous tissue and myelin are ex-
tremely enriched in plasmalogens. In myelin, plasmalogens have been
localized to the inner leaﬂet of myelin and seminal work has showed
their contribution to the structure and stability of myelin [111].
The usage ofmousemodelswith defects in plasmalogens has greatly
increased our knowledge as to the consequences of plasmalogen loss to
the central and peripheral nervous system (CNS and PNS, respectively).
In the CNS a deﬁciency in plasmalogens leads to (a) optic nerve hypo-
plasia, (b) impaired myelination, (c) astrocytosis, (d) impaired Purkinje
cell innervation andmay alsomodulate neuronalmigration. In the PNS a
deﬁciency in plasmalogens affects (a) nerve conduction, (b)myelination
and (c) myelinated axons.
Impaired cortical neuronal migration is readily observed in Pex5
KO mice (a model for Zellweger syndrome) and surprisingly Pex7
KO mice also showed a defect in cortical neuronal migration [9,87].
The defect in Pex7 KO mice is not as severe as in Pex5 KO mice
which, suggests that the impairment in neuronal migration observed
in Pex5mutant mice and in Zellweger patients may be in part due to a
combined defect in plasmalogens and accumulation of VCLFA. Re-
cently, a double Gnpat:Mfp2 KO was generated in order to evaluate
the consequences of a plasmalogen deﬁciency combined with that
of a total defect in peroxisomal β-oxidation [75]. This Gnpat:Mfp2
double mutant showed minor defects in cortical migration and cere-
bellar foliation, that were milder than those present in Pex7 KO
mice. Although the two models (i.e., Pex7 KO and Gnpat:Mfp2 DKO)
share a defect in plasmalogens the defects in β-oxidation are differ-
ent, with Pex7 KO mice having an accumulation of VLCFA and Mfp2
having an accumulation of VLCFA, bile acid intermediates and pri-
stanic acid. In addition the results obtained may also suggest that a
yet undetermined PTS2 protein, that would be deﬁcient in Pex7 KO
mice but not in Gnpat KO mice, is important during the process of
neuronal migration. Recently, a comparative proteomic analysis has
identiﬁed a new PTS2 candidate protein in mouse kidney [112]. Sim-
ilar approaches using nervous tissue samples from WT and Pex7 KO
mice may also uncover nervous tissue-speciﬁc PTS2 proteins.
Optic nerve hypoplasia was ﬁrst observed in Gnpat KO mice, but it
is also present in Pex7 KO mice (Brites et al., unpublished results).
Optic nerves from Gnpat KO mice showed a decrease in the number
of large myelinated axons, and evidences of degeneration in the
form of axonal swellings and increased length of the non-
myelinated portion of the optic nerve. A detailed histological and
morphometric analysis should result in the deeper understanding
on the consequences of plasmalogen deﬁcits to axons and myelin in
the optic nerve. Nevertheless the consequences of a plasmalogen de-
ﬁciency to myelination in the CNS are readily seen in the corpus cal-
losum and cerebellum of Pex7 and Gnpat KO mice. Thinner white
matter tracks are observed in aged Pex7 KO mice indicative of demy-
elination [89], whereas in young Gnpat KO mice dysmyelination is
observed in the cerebellar vermis and terminal regions of cerebellar
lobules [96]. In the cerebellum, Purkinje cell abnormalities were alsofound in relation to innervation with abnormal spinogenesis and syn-
aptogenesis [96].
In the PNS, a deﬁciency in plasmalogens affects nerve conduction
and immunohistological assessment of sciatic nerves with an anti-
body against myelin basic protein reveals the loss of myelinated ﬁbers
and a reduction in the amount of myelin around axons [89]. Com-
bined with the electrophysiological data, the results indicate that
Pex7 KO mice develop a peripheral neuropathy, but further studies
should aim at understanding the consequences of plasmalogen loss
to neurons and/or to Schwann cells.
6. Mice as models for human disorders
Currently there are four mouse models for RCDP. The availability
of straight KOs and hypomorphic mutants will undoubtedly allow a
better understanding on the consequences of a deﬁciency in
plasmalogens, since both sets of mice mimic different aspects of the
human disease. At the biochemical level all models show defects in
the biosynthesis of plasmalogens that correspond with what is
known for RCDP patients. The phenotype of these plasmalogen-
deﬁcient mice is strikingly similar among them. As reviewed here,
all mutant mice show defects in the lens (leading to cataract forma-
tion) and the testis (leading to male infertility). The detailed charac-
terization of the mutant phenotype has also revealed that a
deﬁciency in plasmalogens also affects ossiﬁcation and myelination.
Some mild variations with less pronounced pathology may be ob-
served in the hypomorphic mutants (e.g., myelin defects in Pex7
hypomorphic mouse when compared to Gnpat KO mouse). These
may be explained by the differences in expression and the residual
plasmalogen levels present in hypomorphic mutant when compared
to the KO mutants.
The available mouse mutants serve as good models for the human
disorder. In the last years, following the ﬁrst publications on the gen-
eration of these mouse models it has become evident that soon their
characterization will surpass that of the human disease (e.g. the de-
fects in myelin, and in testis are poorly characterized in RCDP pa-
tients). Although these mice were in part generated to better
understand the human condition and to serve as tools to test thera-
peutic interventions, they are allowing the determination and charac-
terization of pathologies that have not been described in RCDP
patients. Although some care must be given to some of the “new” pa-
thologies described in plasmalogen-deﬁcient mice, it should be em-
phasized that the usage of mouse models does not exclude the need
to perform similar analyses in tissues or cells from RCDP patients.
The inability to gain access to postmortem material hinders such
studies but only with them can we ascertain the true relevance of
the murine ﬁndings to human health and better management of the
disease state in RCDP patients.
7. Concluding remarks
Plasmalogens are a unique phospholipid that despite their obscure
nature, composition and biosynthesis have been shown crucial for
human health. A deﬁciency in plasmalogens affects multiple cells in
a wide variety of tissues and organs. This myriad of presentations
and defects is nevertheless confusing due to the fact that based on
the proposed functions of plasmalogens no given role can unify the
pathology and explain the disease mechanism. The generation and
usage of mouse models with defects in the biosynthesis of
plasmalogens is shedding new knowledge into the pathology and
will serve as excellent tools in which we can investigate and deter-
mine the mechanisms behind the observed pathology. The strengths
of these mouse mutants are also in their usage as models, in which re-
searchers and physicians can devise and test therapeutic interven-
tions [113,114].
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